| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
701.66(B) |
| Last
Volume: |
2,008,266 |
Avg
Vol: |
3,289,637 |
| 52
Week Range: |
$390.35 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
644,570 |
871,420 |
3,176,506 |
6,211,418 |
| Total Sell Value |
$465,524,857 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
8 |
14 |
47 |
89 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walker Karen |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$200,196 |
D/D |
335 |
5,909 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$204,977 |
D/D |
343 |
2,057 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$214,538 |
D/D |
359 |
15,515 |
|
- |
|
| Ricks David A |
President, Chair, and CEO |
• • – |
2023-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,000 |
425,443 |
|
- |
|
| Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
17 |
105,321 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-11-06 |
4 |
AS |
$571.10 |
$382,637 |
D/D |
(670) |
4,708 |
|
28% |
|
| Johnson Kimberly H |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$9,866 |
D/D |
16 |
2,197 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$4,933 |
D/D |
8 |
1,714 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$9,866 |
D/D |
16 |
1,051 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$14,183 |
D/D |
23 |
15,156 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$11,100 |
D/D |
18 |
53,397 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-10-16 |
4 |
A |
$616.64 |
$9,866 |
D/D |
16 |
71,384 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2023-10-11 |
4 |
S |
$603.24 |
$130,169,879 |
D/D |
(215,000) |
99,768,810 |
|
-23% |
|
| Greene Gabrielle E |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$5,142 |
D/D |
9 |
1,706 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$9,712 |
D/D |
17 |
71,368 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$14,282 |
D/D |
25 |
15,133 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$9,712 |
D/D |
17 |
1,035 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$9,712 |
D/D |
17 |
2,181 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-09-18 |
4 |
A |
$571.28 |
$11,426 |
D/D |
20 |
53,379 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-09-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
760 |
7,000 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-09-12 |
4 |
AS |
$590.98 |
$678,445 |
D/D |
(1,148) |
7,760 |
|
5% |
|
| Lilly Endowment Inc |
|
– – • |
2023-09-07 |
4 |
S |
$565.14 |
$119,995,275 |
D/D |
(210,000) |
99,983,810 |
|
-10% |
|
| Lilly Endowment Inc |
|
– – • |
2023-08-30 |
4 |
S |
$554.17 |
$3,432,417 |
D/D |
(6,181) |
100,240,351 |
|
-14% |
|
| Lilly Endowment Inc |
|
– – • |
2023-08-29 |
4 |
S |
$554.08 |
$15,928,697 |
D/D |
(28,747) |
100,246,532 |
|
-13% |
|
| Lilly Endowment Inc |
|
– – • |
2023-08-28 |
4 |
S |
$555.54 |
$2,147,483,647 |
D/D |
(37,660) |
100,275,279 |
|
-12% |
|
1437 Records found
|
|
Page 4 of 58 |
|
|
8.64 (1.19%) 
